Using Clonidine to Improve Leg Weakness in People With Heart Failure
Primary Purpose
Heart Failure
Status
Completed
Phase
Phase 4
Locations
United States
Study Type
Interventional
Intervention
Clonidine Patch
Matching Placebo Patch
Sponsored by

About this trial
This is an interventional basic science trial for Heart Failure focused on measuring Leg Weakness, Skeletal Myopathy, Sympathetic Nerve Activity
Eligibility Criteria
Inclusion Criteria:
- Heart failure
Exclusion Criteria:
- Currently on Coumadin therapy
- Experienced a heart attack in the 3 months before study entry
- Medically unable to receive clonidine
- Advanced kidney or liver disease
Sites / Locations
- University of California, Los Angeles Medical Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Clonidine patch
Placebo
Arm Description
Participants assigned to wear a clonidine patch.
Participants assigned to wear a matching placebo patch.
Outcomes
Primary Outcome Measures
Change in Citrate Synthase Activity as an Estimate of Mitochondrial Activity
Secondary Outcome Measures
Change in Proportion of Type 1 Fibers
Fibers were typed as I or II according to presence of myosin heavy chain.
Full Information
NCT ID
NCT00858845
First Posted
March 6, 2009
Last Updated
April 26, 2018
Sponsor
University of California, Los Angeles
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
1. Study Identification
Unique Protocol Identification Number
NCT00858845
Brief Title
Using Clonidine to Improve Leg Weakness in People With Heart Failure
Official Title
Clonidine and the Skeletal Myopathy of Heart Failure
Study Type
Interventional
2. Study Status
Record Verification Date
April 2018
Overall Recruitment Status
Completed
Study Start Date
May 2008 (undefined)
Primary Completion Date
March 2011 (Actual)
Study Completion Date
December 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Los Angeles
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
People with heart failure often have weakness in their leg muscles. This study will determine whether the leg weakness is due to very high adrenaline levels and whether the medication clonidine can improve leg weakness.
Detailed Description
Heart failure is a common condition, affecting approximately 5 million people in the United States. People with heart failure are encouraged to exercise and lose weight. However, many people with heart failure develop weakness in their leg muscles, which can make exercise difficult. Increased sympathetic nerve activity, which involves the nerves that carry adrenaline, also occurs in people with heart failure. It is possible that the increased sympathetic nerve activity may actually cause the leg muscle weakness. Clonidine, a medication used to treat high blood pressure, has been found to decrease sympathetic nerve activity. This study will further examine the connection between leg weakness and sympathetic nerve activity. It will also evaluate the effectiveness of clonidine at decreasing leg weakness in people with heart failure. Results from this study may explain why some people with heart failure are unable to exercise and may help to identify ways in which leg strength can be increased.
This study will enroll people with heart failure. Participants will be randomly assigned to wear either a clonidine patch or a placebo patch for 3 months. Participants will wear the patch on their upper arm, and they will replace the patch each week. At study visits at baseline and Month 3, participants will undergo the following procedures:
Sympathetic nerve activity recording, which will record nerve activity in the lower leg, using small electrodes inserted through the skin
Muscle biopsy, in which a small piece of muscle tissue will be obtained from participants' legs
Heart rate and blood pressure measurements
Arterial baroreceptor measurements, in which the nerves in the body that respond to changes in blood pressure will be examined while participants receive different medications to increase and decrease their blood pressure
Echocardiography to obtain images of the heart
Magnetic resonance scan of the leg
Passive exercise procedure, in which study researchers will conduct an arm exercise with participants
There will be no follow-up visits.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure
Keywords
Leg Weakness, Skeletal Myopathy, Sympathetic Nerve Activity
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
11 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Clonidine patch
Arm Type
Experimental
Arm Description
Participants assigned to wear a clonidine patch.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants assigned to wear a matching placebo patch.
Intervention Type
Drug
Intervention Name(s)
Clonidine Patch
Other Intervention Name(s)
Catapres-TTS
Intervention Description
A clonidine patch (0.1 mg/week) to be worn for a period of 3 months.
Intervention Type
Other
Intervention Name(s)
Matching Placebo Patch
Intervention Description
A matching placebo patch to be worn for a period of 3 months.
Primary Outcome Measure Information:
Title
Change in Citrate Synthase Activity as an Estimate of Mitochondrial Activity
Time Frame
Baseline, 3 months
Secondary Outcome Measure Information:
Title
Change in Proportion of Type 1 Fibers
Description
Fibers were typed as I or II according to presence of myosin heavy chain.
Time Frame
Baseline, 3 months
Other Pre-specified Outcome Measures:
Title
Change in Muscle Sympathetic Nerve Activity
Description
Muscle sympathetic nerve activity was measured as bursts sympathetic nerve activity per minute.
Time Frame
Baseline, 3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Heart failure
Exclusion Criteria:
Currently on Coumadin therapy
Experienced a heart attack in the 3 months before study entry
Medically unable to receive clonidine
Advanced kidney or liver disease
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Holly R. Middlekauff, MD
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, Los Angeles Medical Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
23575739
Citation
Middlekauff HR, Verity MA, Horwich TB, Fonarow GC, Hamilton MA, Shieh P. Intact skeletal muscle mitochondrial enzyme activity but diminished exercise capacity in advanced heart failure patients on optimal medical and device therapy. Clin Res Cardiol. 2013 Aug;102(8):547-54. doi: 10.1007/s00392-013-0564-3. Epub 2013 Apr 11.
Results Reference
result
Learn more about this trial
Using Clonidine to Improve Leg Weakness in People With Heart Failure
We'll reach out to this number within 24 hrs